Scholarlink

Objective <p>Cerebral venous thrombosis (CVT) presents clinical challenges due to non-specific symptoms and limited biomarkers for assessing severity. Effective treatments for severe CVT are lacking. This study investigates inflammatory biomarkers linked to disease severity and evaluates glucocorticoids’ therapeutic potential in severe CVT.</p> Methods <p>A prospective cohort study of 78 CVT patients assessed disease severity using neurological scores and analyzed inflammatory biomarkers, including hs-CRP, IL-6, neutrophil count, lymphocyte count, and NLR. Changes in severity and biomarkers were evaluated before and after glucocorticoid treatment.</p> Results <p>Severe CVT patients had elevated high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and neutrophil percentage, with reduced lymphocyte counts compared to non-severe cases. Neutrophil count, NLR, hs-CRP, and IL-6 positively correlated with neurological scores at admission, while lymphocyte percentage showed a negative correlation. Glucocorticoid treatment improved neurological function and reduced hs-CRP and IL-6 levels, suggesting anti-inflammatory benefits.</p> Conclusion <p>Neutrophils, hs-CRP, and IL-6 are promising biomarkers for CVT severity and treatment response. Glucocorticoids may improve outcomes by modulating inflammation, warranting further research into their mechanisms and long-term efficacy in CVT management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inflammatory markers and clinical outcomes in acute/subacute severe cerebral venous thrombosis: the role of glucocorticoid therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月11日

查看全文
  • Xue Li,
  • Shuyuan Hu,
  • Qi Kong,
  • Yiwei Zhang,
  • Xunming Ji,
  • Haiping Zhao,
  • Jiangang Duan

摘要

Objective

Cerebral venous thrombosis (CVT) presents clinical challenges due to non-specific symptoms and limited biomarkers for assessing severity. Effective treatments for severe CVT are lacking. This study investigates inflammatory biomarkers linked to disease severity and evaluates glucocorticoids’ therapeutic potential in severe CVT.

Methods

A prospective cohort study of 78 CVT patients assessed disease severity using neurological scores and analyzed inflammatory biomarkers, including hs-CRP, IL-6, neutrophil count, lymphocyte count, and NLR. Changes in severity and biomarkers were evaluated before and after glucocorticoid treatment.

Results

Severe CVT patients had elevated high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and neutrophil percentage, with reduced lymphocyte counts compared to non-severe cases. Neutrophil count, NLR, hs-CRP, and IL-6 positively correlated with neurological scores at admission, while lymphocyte percentage showed a negative correlation. Glucocorticoid treatment improved neurological function and reduced hs-CRP and IL-6 levels, suggesting anti-inflammatory benefits.

Conclusion

Neutrophils, hs-CRP, and IL-6 are promising biomarkers for CVT severity and treatment response. Glucocorticoids may improve outcomes by modulating inflammation, warranting further research into their mechanisms and long-term efficacy in CVT management.